FTLF FITLIFE BRANDS, INC.

Nasdaq Medicinal Chemicals & Botanical Products NV CIK: 0001374328
AI RATING
BUY
72% Confidence

Investment Thesis

FitLife Brands demonstrates strong fundamental growth with 22.3% YoY revenue expansion and exceptional 69.6% net income growth, supported by healthy 40.5% gross margins and 14.0% operating margins. The company generates solid free cash flow of $7.2M with a 12.9% FCF margin, though elevated leverage (1.11x Debt/Equity) and tight liquidity (1.13x current ratio) require monitoring as the company scales.

Strengths

  • + Strong revenue growth of 22.3% YoY with net income growth of 69.6% indicating operational leverage
  • + Healthy profitability metrics with 40.5% gross margin and 14.0% operating margin in medicinal/botanical sector
  • + Solid free cash flow generation of $7.2M with 12.9% FCF margin demonstrating cash conversion ability
  • + Strong interest coverage ratio of 18.8x indicates sufficient earnings to service debt obligations

Risks

  • ! Elevated leverage with 1.11x Debt/Equity ratio and $46.5M long-term debt against $41.9M equity
  • ! Tight liquidity position with 1.13x current ratio and low cash balance of $3.5M relative to $68.1M liabilities
  • ! Quick ratio of 0.46x suggests potential working capital stress if inventory cannot be quickly liquidated
  • ! No recent insider buying activity (0 Form 4 filings in 90 days) may indicate limited management confidence

Key Metrics to Watch

Financial Metrics

Revenue
55.5M
Net Income
4.7M
EPS (Diluted)
$0.47
Free Cash Flow
7.2M
Total Assets
110.0M
Cash
3.5M

Profitability Ratios

Gross Margin 40.5%
Operating Margin 14.0%
Net Margin 8.4%
ROE 11.2%
ROA 4.3%
FCF Margin 12.9%

Balance Sheet & Liquidity

Current Ratio
1.13x
Quick Ratio
0.46x
Debt/Equity
1.11x
Debt/Assets
61.9%
Interest Coverage
18.83x
Long-term Debt
46.5M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-03-25T09:22:11.287922 | Data as of: 2025-09-30 | Powered by Claude AI